Does paracetamol potentiate the effects of oral anticoagulants? A literature review

Drug Safety

Volumn 27, Issue 5, 2004, Pages 325-333

  Mahé, Isabelle ^a   Caulin, Charles ^a   Bergmann, Jean François ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANALGESIC AGENT; ANISINDIONE; ANTICOAGULANT AGENT; ANTIPYRETIC AGENT; COUMARIN; NON PRESCRIPTION DRUG; PARACETAMOL; PHENPROCOUMON; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CANCER; CANCER PAIN; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG HALF LIFE; DRUG INTOXICATION; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; EMBASE; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HEART ATRIUM FIBRILLATION; HEMATOMA; HEMATURIA; HUMAN; LITERATURE; LIVER METABOLISM; MEDLINE; PATHOPHYSIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; THROMBOEMBOLISM;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANTICOAGULANTS; CLINICAL TRIALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG SYNERGISM; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE;

EID: 1942531972     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427050-00004     Document Type: Review

References (40)

1. Hirsch J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S
2. Levine MN, Raskob G, Landefeld S, et al. Haemorrhagic complications of anticoagulant treatment. Chest 2001; 119: 108S-21S
3. Hylek EM, Singer DE. Risk factors for intracranial haemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902
4. Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. Drugs Aging 2003; 20 (1): 23-57
5. Meagher EA. Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications. Drug Saf 2003; 26 (13): 913-24
6. Karim A, Tolbert D, Piergies A, et al. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects. J Clin Pharmacol 2000; 40: 655-63
7. Schwartz JI, Bugianesi KJ, Ebel DL, et al. The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin. Clin Pharmacol Ther 2000; 68: 626-36
8. Mersfelder TL, Stewart LR. Warfarin and celecoxib interaction. Ann Pharmacother 2000; 34: 325-7
9. Haase KK, Rojas-Fernandez CH, Lane L, et al. Potential interaction between celecoxib and warfarin. Ann Pharmacother 2000; 34: 666-7
10. US Food and Drug Administration safety alert [online]. Available from URL: http://www.fda.gov/medwatch/safety/1999/celebr.htm [Accessed 1999 Jun]
11. Josefson D. FDA warns Merck over its promotion of rofecoxib [news]. BMJ 2001; 323: 767
12. Woodwell DL. National Ambulatory Medical Care Survey: 1996 summary. Hyattsville (MD): National Center for Health Statistics; 1997. Advance Data from Vital and Health Statistics, No. 295
13. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279: 657-62
14. Antlitz AM, Mead Jr JA, Tolentino MA. Potentiation of oral anticoagulant therapy by paracetamol. Curr Ther Res Clin Exp 1968; 10: 501-7
15. Antlitz AM, Await LF. A double blind study of paracetamol used in conjunction with oral anticoagulant therapy. Curr Ther Res Clin Exp 1969; 11: 360-1
16. Rubin RN, Metzer RL, Budzynski AZ. Potentiation of anticoagulation effects of warfarin by paracetamol (tylenol) [abstract]. Clin Res 1984; 32: 698a
17. Udall JA. Drug interference with warfarin therapy. Clin Med 1970; 77: 20-5
18. Kwan D, Bartle WR, Walker SE. The effects of paracetamol on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39: 68-75
19. Fattinger K, Frisullo R, Masche U, et al. No clinically relevant drug interaction between paracetamol and phenprocoumon based on a pharmacoepidemiological cohort study in medical inpatients. Eur J Clin Pharmacol 2002; 57: 863-7
20. Boeijinga JJ, Boerstra EE, Ris P, et al. Interaction between paracetamol and coumarin anticoagulants [letter]. Lancet 1982; I: 506
21. Bartle WR, Blakely JA. Potentiation of warfarin anticoagulation by paracetamol [letter]. JAMA 1991; 265: 1260
22. Andrews FJ. Retroperitoneal haematoma after paracetamol increased anticoagulation. Emerg Med J 2002; 19: 84-5
23. Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al. Warfarin and paracetamol interaction. Pharmacotherapy 2003; 23: 109-12
24. Bagheri H, Bernhard NB, Montastruc JL. Potentiation of the acenocoumarol anticoagulant effect by paracetamol [letter]. Ann Pharmacother 1999; 33: 506
25. Bell WR. Acetaminophen and warfarin: undesirable synergy. JAMA 1998; 279: 702-3
26. Whyte IM, Buckley NA, Reith DM, et al. Acetaminophen causes an increased international normalized ratio by reducing functional factor VII. Ther Drug Monit 2000; 22: 742-8
27. Lehmann DE. Enzymatic shunting: resolving the paracetamol - warfarin controversy. Pharmacotherapy 2000; 20: 1464-8
28. Black M. Acetaminophen hepatotoxicity. Gastroenterology 1980; 78: 382-92
29. Slattery JT, Gerhard L. Acetaminophen kinetics in acutely poisoned patients. Clin Pharmacol Ther 1979; 25: 184-95
30. Thummel KT, Lee CA, Kunze KL, et al. Oxidation of paracetamol to N-acetyl-p-aminobenzoquinone imine by human CYP 3A4. Biochem Pharmacol 1993; 45: 1563-9
31. Shek KL, Chan LN, Nutescu E. Warfarin-paracetamol drug interaction revisited. Pharmacotherapy 1999; 19: 1153-8
32. Tanaka E. In vivo age-related changes in hepatic drug-oxidising capacity in humans. J Clin Pharm Ther 1998; 23: 247-55
33. Shan X, AW YT, Smith ER, et al. Effect of chronic hypoxia on detoxification enzymes in rat liver. Biochem Pharmacol 1992; 43: 2421-6
34. Bonkovsky HL, Kane RE, Jones DP, et al. Acute hepatic and renal toxicity from low doses of paracetamol in the absence of alcohol abuse or malnutrition: evidence for increased susceptibility to drug toxicity due to cardiopulmonary and renal insufficiency. Hepatology 1994; 19: 1441-8
35. Schlant RC, Sonnenblick EH, Katz AM. Pathophysiology of heart failure. In: Alexander RW, Schlant RC, Fuster V, editors. Hurst's the heart. 9th ed. New York: McGraw-Hill Inc, 1998: 710
36. Newman JH, Ross JC. Chronic cor pulmonale. In: Alexander RW, Schlant RC, Fuster V, editors. Hurst's the heart. 9th ed. New York: McGraw-Hill Inc, 1998: 1746
37. Mason JW. Classification of cardiomyopathies. In: Alexander RW, Schlant RC, Fuster V, editors. Hurst's the heart. 9th ed. New York: McGraw-Hill Inc, 1998: 2031-8
38. Riser J, Gilroy C, Hudson P, et al. Acetaminophen and risk factors for excess anticoagulation with warfarin [letter]. JAMA 1998; 280: 696
39. Fitzmaurice DA, Murray JA. Potentiation of the anticoagulant effect of warfarin. Postgrad Med J 1997; 73: 439-40
40. Amato MG, Bussey H, Farnett L, et al. Acetaminophen and risk factors for excess anticoagulation with warfarin. JAMA 1998; 280: 695-6